Hematology-American Society of Hematology Education Program

(The TQCC of Hematology-American Society of Hematology Education Program is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
Managing toxicities of Bruton tyrosine kinase inhibitors77
Therapeutic development and current uses of BCL-2 inhibition68
Platelet transfusion refractoriness: how do I diagnose and manage?40
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors39
Preventing infections in children and adults with asplenia38
Bispecifics, trispecifics, and other novel immune treatments in myeloma38
Monoclonal gammopathies of clinical significance37
Updates in infection risk and management in acute leukemia34
Gene therapy for hemophilia33
Therapy for lower-risk MDS32
Management of AL amyloidosis in 202032
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes30
Next-generation cell therapies: the emerging role of CAR-NK cells27
Inferior vena cava filters: a framework for evidence-based use26
Updates in chronic graft-versus-host disease23
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review23
Does ABO and RhD matching matter for platelet transfusion?23
Management of Waldenström macroglobulinemia in 202023
Advances in the management of α-thalassemia major: reasons to be optimistic22
Have we reached a molecular era in myelodysplastic syndromes?22
Outpatient transfusions for myelodysplastic syndromes22
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry21
Future of CAR T cells in multiple myeloma21
Combining antiplatelet and anticoagulant therapy in cardiovascular disease20
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia20
Gene therapy for sickle cell disease: where we are now?19
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di19
Dyskeratosis congenita and telomere biology disorders19
What to use to treat AML: the role of emerging therapies19
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management19
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics19
Allogeneic hematopoietic cell transplantation for older patients19
Modern management of Fanconi anemia19
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?18
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?17
Antibodies and bispecifics for multiple myeloma: effective effector therapy16
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes16
Identifying potential germline variants from sequencing hematopoietic malignancies16
Increasing access to allogeneic hematopoietic cell transplant: an international perspective16
High-risk multiple myeloma: how to treat at diagnosis and relapse?16
Optimizing the management of chronic pain in sickle cell disease16
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)16
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease15
Approach to the patient with suspected hypereosinophilic syndrome15
Does aspirin prevent venous thromboembolism?15
Women and bleeding disorders: diagnostic challenges15
Management of heavy menstrual bleeding on anticoagulation15
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management14
Double-hit lymphoma: optimizing therapy14
Chemotherapy-free frontline therapy for CLL: is it worth it?14
Epidemiology and treatment of priapism in sickle cell disease14
Blast and accelerated phase CML: room for improvement14
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings14
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms14
Challenges in chronic transfusion for patients with thalassemia14
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban14
How to recognize and manage COVID-19-associated coagulopathy13
How do we sequence therapy for marginal zone lymphomas?13
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation13
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop13
Indications for transfusion in the management of sickle cell disease13
Relapsed ALL: CAR T vs transplant vs novel therapies13
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs12
Transformed lymphoma: what should I do now?12
Cellular therapy for multiple myeloma: what's now and what's next12
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP12
How to manage CML patients with comorbidities12
Mechanisms of somatic transformation in inherited bone marrow failure syndromes12
Hemophilia gene therapy: ushering in a new treatment paradigm?12
Global look at nutritional and functional iron deficiency in infancy11
Molecular prognostication in Ph-negative MPNs in 202211
Extrahematopoietic manifestations of the short telomere syndromes11
Diamond-Blackfan anemia11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency11
Inherited microcytic anemias11
COVID-19 and thrombosis: searching for evidence11
Heparin-induced thrombocytopenia and cardiovascular surgery11
Genomics of MPN progression11
How to evaluate and treat the spectrum of TMA syndromes in pregnancy11
Lower risk but high risk10
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?10
Treatment of Richter's syndrome10
Sequencing multiple myeloma therapies with and after antibody therapies10
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies10
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events10
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas10
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life10
Direct oral anticoagulant (DOAC) interference in hemostasis assays10
Achieving MRD negativity in AML: how important is this and how do we get there?10
Novel targets in aggressive lymphoma9
Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax9
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation9
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?9
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy9
How immunodeficiency can lead to malignancy9
Hematology 2022—what is complete HLA match in 2022?9
Transplant for TP53-mutated MDS and AML: because we can or because we should?9
CAR T cells vs allogeneic HSCT for poor-risk ALL9
When does a PNH clone have clinical significance?9
In 2022, which is preferred: haploidentical or cord transplant?9